• Kirin announced final results from the German real-world MINT study of Poteligeo for mycosis fungoides and Sézary syndrome.
• Results were presented at the EORTC-CLTG Annual Meeting 2026 in Berlin.
• Study showed durable disease control in routine practice, with meaningful response rates and quality-of-life gains.
• Exploratory subgroup findings supported use across harder-to-treat patient types, reinforcing the drug’s positioning in clinical practice.
• Safety profile broadly matched prior pivotal-trial experience, with treatment-related side effects sometimes leading to discontinuation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kirin Holdings Company Limited published the original content used to generate this news brief via Business Wire (Ref. ID: 202610120200BIZWIRE_USPR_____20261011_BW759691) on October 12, 2026, and is solely responsible for the information contained therein.